A Bristol-based company, which has developed faster and
cheaper ways to identify harmful bacteria has received financial backing from
eight of the city’s successful entrepreneurs.

FluoretiQ, based in Unit DX, Bristol, is a two-year old business that is using novel technology to identify bacterial infections in hospitals, clinics and care homes. It sourced some of its latest financial support through Bristol Private Equity Club.

Chief executive, Neciah Dorh, who has a PhD in nanophotonics
and a background in fluorescence technologies for bio-sensing, leads the team
who have developed the techniques.

He said: “This support will enable us to push forward with
our ambitious growth plans to revolutionise bacterial diagnostics. We are
passionate about our research and development and have invested in building the
team we need to deliver this technology to people all over the world.

“The technology can reduce clinical decision-making time
from 48 hours to 15 minutes, an accelerated approach to existing care pathways.
At the moment we are working on a solution for urinary tract infections, to reduce
recurrent GP visits, hospitalisation and unnecessary prescription of broad
spectrum antibiotics.

“We have always worked closely in collaboration with the University
of Bristol and to now have other Bristol-based entrepreneurs recognising the
potential of FluoretiQ is a huge boost and encouragement to us as a business.”

Jerry Barnes, founder of the Bristol Private Equity Club,
said: “Bristol is fast gaining a reputation for the number of companies like
FluoretiQ that are using emerging technology to make a real difference to the

“We have 80 successful entrepreneurs and business people with
capital in the club. They all want to support fast growing and successful
businesses and to share the expertise and lessons they have learned over the
years with those at the leading edge of development.”

Bristol Private Equity Club has now invested a total of £6 million in three years in 19 Bristol area businesses. FluoretiQ was developed with venture capital from Deepbridge Capital and now has a strong scientific team taking the research forward.

Issued on behalf of Bristol Private Equity Club by Empica